Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vaping 1Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Stomach Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Neoplasms by Histologic Type 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11aflutinib 9Drug Therapy 9Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × BID protein, human × Clear all
NCT04820023 2025-06-06

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Bridge Biotherapeutics, Inc.

Phase 1/2 Terminated
45 enrolled 19 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡